<DOC>
	<DOC>NCT00936260</DOC>
	<brief_summary>The purpose of this study is to determine the duration of the treatment with alendronate in postmenopausal women with osteoporosis.</brief_summary>
	<brief_title>Drug Holidays in the Treatment With Alendronate in Postmenopausal Women With Osteoporosis</brief_title>
	<detailed_description>The duration of the treatment with alendronate is not well established. The investigators recruited 228 women with postmenopausal osteoporosis. They all received alendronate during the first 3 years of monitoring and were later on randomized to whether different regimens of intermittent treatment or to carry on 3 years more.</detailed_description>
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Alendronate</mesh_term>
	<criteria>postmenopausal osteoporosis under densitometric criteria of the World Health Organization secondary osteoporosis alteration in analytic parameters (total proteins, calcium, phosphorus, vitamin D, parathyroid hormone, thyroid hormone, transaminase, creatinine)</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 1998</verification_date>
	<keyword>osteoporosis</keyword>
	<keyword>postmenopausal</keyword>
	<keyword>alendronate</keyword>
</DOC>